Portal de investigación
Lipid-Polyglutamate Nanoparticle Vaccine Platform
Fecha de publicación:
Fecha Ahead of Print:
Autores de CIPF
Participantes ajenos a CIPF
- Van Lysebetten, D
- Deswarte, K
- Koynov, K
- Golba, B
- Ye, TT
- Zhong, ZF
- Kasmi, S
- Lamoot, A
- Chen, Y
- Van Herck, S
- Lambrecht, BN
- Sanders, NN
- Lienenklaus, S
- David, SA
- De Koker, S
- De Geest, BG
Grupos de Investigación
Abstract
Peptide-based subunit vaccines are attractive in view of personalized cancer vaccination with neo-antigens, as well as for the design of the newest generation of vaccines against infectious diseases. Key to mounting robust antigen-specific immunity is delivery of antigen to antigen-presenting (innate immune) cells in lymphoid tissue with concomitant innate immune activation to promote antigen presentation to T cells and to shape the amplitude and nature of the immune response. Nanoparticles that co-deliver both peptide antigen and molecular adjuvants are well suited for this task. However, in the context of peptide-based antigen, an unmet need exists for a generic strategy that allows for co-encapsulation of peptide and molecular adjuvants due to the stark variation in physicochemical properties based on the amino acid sequence of the peptide. These properties also strongly differ from those of many molecular adjuvants. Here, we devise a lipid nanoparticle (LNP) platform that addresses these issues. Key in our concept is poly(L-glutamic acid) (PGA), which serves as a hydrophilic backbone for conjugation of, respectively, peptide antigen (Ag) and an imidazoquinoline (IMDQ) TLR7/8 agonist as a molecular adjuvant. Making use of the PGA's polyanionic nature, we condensate PGA-Ag and PGA-IMDQ into LNP by electrostatic interaction with an ionizable lipid. We show in vitro and in vivo in mouse models that LNP encapsulation favors uptake by innate immune cells in lymphoid tissue and promotes the induction of Ag-specific T cells responses both after subcutaneous and intravenous administration.
Datos de la publicación
- ISSN/ISSNe:
- 1944-8244, 1944-8252
- Tipo:
- Article
- Páginas:
- 6011-6022
- PubMed:
- 33507728
ACS Applied Materials & Interfaces AMER CHEMICAL SOC
Citas Recibidas en Web of Science: 28
Documentos
- No hay documentos
Filiaciones
Keywords
- vaccine; lipid nanoparticles; peptides; TLR agonists
Proyectos asociados
Ensuring long-term sustainability of excellence in chemical biology within Europe and beyond
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2019
Combinatory treatment of Neural precursor cells and a new nanoconjugate of Fasudil for the clinical application in Acute Spinal Cord Injury
Investigador Principal: MARIA JESUS VICENT DOCON
FUNDACION LA MARATO DE TV3 . 2018
RTC-2017-6600-1 Desarrollo de una plataforma de terapia génica para enfermedades genéticas renales
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2018
Desarrollo de terapias tópicas basadas en sistemas de transporte polipeptídicos
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2018
SENSITIZING PANCREATIC CANCER TO IMMUNOTHERAPY WITH MULTIMODAL PRECISION NANOMEDICINES
Investigador Principal: MARIA JESUS VICENT DOCON
FUNDACIÓN LA CAIXA . 2019
Molecular Machines Functioning in Cells
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2020
Aproximación sinérgica al desarrollo de terapias para tumores metastásicos y desórdenes neurodegenarativos utilizando conjugados polipetídicos versátiles
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2020